Molecular modelling of the structure and evaluation of the chemical shifts of 1H and 13C nuclei were performed for the 4-[4-(2-aminoethoxy)benzyl]aniline, which is a structural analogue of thyronamines. The intramolecular dynamics of the key structural fragments of 4-[4-(2-aminoethoxy)benzyl]aniline were studied by the PM6-DH2 method as well as at the B3LYP/6-31G(d,p) level of theory. Nonspecific solvation with dimethyl sulfoxide was taken into account within the polarized continuum model. Specific solvation by one and two DMSO molecules was considered within supermolecule approximation. Chemical shifts of the 1H and 13C nuclei were estimated for the most stable conformer of 4-[4-(2-aminoethoxy)benzyl]aniline as well as for its solvates with DMSO. Calculated chemical shifts of the 1H and 13C nuclei are in good agreement with the experimental ones obtained for 4-[4-(2-aminoethoxy)benzyl]aniline in DMSO-d6 solution. Some aspects of the bioactivity of 4-[4-(2-aminoethoxy)benzyl]aniline are discussed.
30 June 2026 in Annals of Clinical and Experimental Neurology
Introduction. Therapeutic options for ischemic stroke (IS) are largely limited to reperfusion, underscoring the importance of exploring new approaches to neuroprotection and neurorepair. Thyronamines — endogenous derivatives of thyroid hormones — are a promising class of compounds with putative neuroprotective potential. Study aim: To evaluate the effect of a synthetic thyronamine analog (SA-T0AM) on the levels of brain damage markers in a rat model of experimental IS. Materials and methods. The study was performed on 30 male Wistar rats divided into 4 groups: 1) Experimental — induction of focal cerebral cortical ischemia by application of ferric chloride followed by SA-T0AM administration; 2) Control — induction of ischemia without subsequent therapy; 3) Sham operation — all surgical manipulations except application of ferric chloride (0.9% NaCl solution was used); 4) intact animals. On day 3, concentrations of neuroglobin (NGB), glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), and S100B protein were determined in the cerebral hemisphere tissue by enzyme-linked immunosorbent assay (ELISA). Results. Induction of ischemia led to a significant increase in the levels of all studied damage biomarkers in both hemispheres. Surgical intervention (craniotomy) caused a nonspecific increase in GFAP, NSE, and BDNF in all operated groups compared to intact animals. The key difference between the Experimental and Control groups was found in the non-ischemic hemisphere: administration of SA-T0AM was associated with a statistically significant increase in NGB content. Conclusion. The observed selective increase in NGB levels in the contralateral hemisphere following SA-T0AM administration indicates the compound’s ability to activate endogenous neuroprotective mechanisms in response to ischemic injury. This effect may be indirect or it may represent an independent direct action of the agent on neuroglobin expression, which requires further investigation. Although no intergroup differences were found for other brain damage markers (GFAP, NSE, S100B), which may be due to insufficient model sensitivity, the data suggest that further study of SA-T0AM is warranted as a pharmacological postconditioning agent in cerebral ischemia.
The release of reactive oxygen species accompanying oxidative stress is one of the most significant damaging mechanisms during brain ischemia. Some aspects of the neuroprotective activity of the thyronamine T0AM synthetic analogue, 4-[4-(2-aminoethoxy)benzyl]aniline (ABA), were studied and discussed in two independent experiments using a model of acute cerebral ischemia. Antioxidant effects were evaluated in adult male and female Wistar rats (Rattus norvegicus), while neurological outcomes were assessed in adult male outbred white rats. Administration of the ABA in a rat brain hemisphere ischemia model was associated with significant changes in redox markers: malondialdehyde, glutathione peroxidase and superoxide dismutase levels in the ischemic hemisphere. Also, the introduction of ABA into the model of acute cerebral ischemia contributed to a reduction in neurological deficit compared to untreated controls. It was revealed that the considered thyronamine T0AM analogue could control redox status in acute brain ischemia. Mono protonated form of ABA (ABA-H+) is considered to be the main species at pH 6.9–7.2. Structural models of the neutral (ABA), protonated (ABA-H+) thyronamine and its solvate (DMSO…ABA-H+) were used in DFT calculations, followed by estimation of molecular and supramolecular level descriptors.
Wound infections, exacerbated by antibiotic resistance and biofilm formation, necessitate alternative therapeutic options. One promising approach is topical bacteriotherapy with live probiotics. The work aimed to summarize existing research on the multifaceted effects of live probiotics in infected wound healing. The review examines how probiotics directly influence pathogenic wound microflora by competing for adhesion sites and nutrients, secreting antagonistic compounds, altering the wound environment, and promoting co-aggregation. Probiotics’ antibiofilm activity is highlighted, including inhibition of quorum sensing systems and disruption of the extracellular biofilm matrix. Moreover, the review discusses the findings of in vitro and in vivo studies on the effects of live probiotics on macroorganisms. Probiotics have been shown to activate signaling pathways that regulate macrophage shift from a pro-inflammatory (M1) phenotype to a pro-repair (M2) phenotype, cytokine synthesis, keratinocyte and fibroblast migration and proliferation, angiogenesis, and collagen matrix formation. Thus, the multifaceted effects of probiotics cannot be replicated by metabolites or inactivated cells alone, highlighting the need for effective delivery systems for live probiotic cultures in infected wound management.
27 April 2026 in Patient-Oriented Medicine and Pharmacy
Relevance. Trace amine-associated receptor-1 (TAAR1) mediates signaling through a broad spectrum of agonists that function as neuromodulators in classical neurotransmitter systems and may also potentially exert a neuroprotective effect. Objective. The aim of this study was to determine the expression pattern of TAAR1 in brain cells and tissues by analyzing publicly available gene expression databases. Materials and methods. TAAR1 gene expression was analyzed using datasets from the Allen Institute for Brain Science (Human Brain Atlas Microarray, Allen Brain Cell Atlas, Brain Allen Developing Human Brain Atlas, and Whole Mouse Brain Transcriptomic Cell Type Atlas). Results. Analysis of public transcriptomic databases revealed TAAR1 expression in the human cerebral cortex, amygdala, basal ganglia, hippocampus, and thalamus. Marked differences between human and mouse data indicate probable interspecies differences in TAAR1 expression. Conclusion. TAAR1 exhibits a heterogeneous and predominantly low-grade distribution within the central nervous system, highlighting the need for modern single-nucleus/single-cell sequencing methods and the development of in vivo approaches to receptor imaging.